{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:23:09Z","timestamp":1789125789901,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100013732","name":"Injury Science Center, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-026-01474-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:48:00Z","timestamp":1782211680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cThe alternative is they\u2019re not getting care at all\u201d: a qualitative interview study of opioid use disorder treatment providers\u2019 perspectives on quality and appropriateness of telehealth for buprenorphine access"],"prefix":"10.1186","volume":"23","author":[{"given":"Naomi","family":"Zucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana V.","family":"Aronowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"S3","key":"1474_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(S3):954\u201363. https:\/\/doi.org\/10.1007\/s11606-020-06257-4.","journal-title":"J GEN INTERN MED"},{"key":"1474_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.drugalcdep.2018.04.033","volume":"189","author":"RD Ashford","year":"2018","unstructured":"Ashford RD, Brown AM, Curtis B. Systemic barriers in substance use disorder treatment: a prospective qualitative study of professionals in the field. Drug Alcohol Depend. 2018;189:62\u20139. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.04.033","journal-title":"Drug Alcohol Depend"},{"key":"1474_CR3","doi-asserted-by":"publisher","first-page":"108651","DOI":"10.1016\/j.drugalcdep.2021.108651","volume":"221","author":"NY Hall","year":"2021","unstructured":"Hall NY, Le L, Majmudar I, Mihalopoulos C. Barriers to accessing opioid substitution treatment for opioid use disorder: a systematic review from the client perspective. Drug Alcohol Depend. 2021;221:108651. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108651","journal-title":"Drug Alcohol Depend"},{"key":"1474_CR4","doi-asserted-by":"publisher","first-page":"108283","DOI":"10.1016\/j.jsat.2021.108283","volume":"124","author":"SA Clark","year":"2021","unstructured":"Clark SA, Davis C, Wightman RS, Wunsch C, Keeler LAJ, Reddy N, et al. Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island. J Subst Abuse Treat. 2021;124:108283. https:\/\/doi.org\/10.1016\/j.jsat.2021.108283","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"1474_CR5","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1097\/ADM.0000000000000744","volume":"14","author":"J Cantor","year":"2020","unstructured":"Cantor J, Stein BD, Saloner B. Telehealth capability among substance use disorder treatment facilities in counties with high versus low COVID-19 social distancing. J Addict Med. 2020;14(6):e366\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000000744","journal-title":"J Addict Med"},{"key":"1474_CR6","unstructured":"Drug Enforcement Administration. Department of justice, department of health and human services. Expansion of Buprenorphine treatment via telemedicine encounter. 2025 Jan 17."},{"key":"1474_CR7","unstructured":"DEA HHSD. Fourth temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications [Internet]. 90 FR 61301. 2025 Dec 31. Available from: https:\/\/www.federalregister.gov\/documents\/2025\/12\/31\/2025-24123\/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled"},{"issue":"6","key":"1474_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1089\/tmj.2021.0308","volume":"28","author":"AG Guillen","year":"2022","unstructured":"Guillen AG, Reddy M, Saadat S, Chakravarthy B. Utilization of telehealth solutions for patients with opioid use disorder using buprenorphine: a scoping review. Telemed J E Health. 2022;28(6):761\u20137. https:\/\/doi.org\/10.1089\/tmj.2021.0308","journal-title":"Telemed J E Health"},{"key":"1474_CR9","doi-asserted-by":"publisher","unstructured":"Krawczyk N, Rivera BD, King C, Dooling BCE. Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S. Health Affairs Scholar. 2023;1(1):qxad013. https:\/\/doi.org\/10.1101\/2023.03.16.23287373","DOI":"10.1101\/2023.03.16.23287373"},{"issue":"1","key":"1474_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/08897077.2021.1967836","volume":"43","author":"B Chan","year":"2022","unstructured":"Chan B, Bougatsos C, Priest KC, McCarty D, Grusing S, Chou R. Opioid treatment programs, telemedicine and COVID-19: a scoping review. Subst Abus. 2022;43(1):539\u2013546","journal-title":"Subst Abus"},{"key":"1474_CR11","doi-asserted-by":"publisher","first-page":"557275","DOI":"10.3389\/fpubh.2020.557275","volume":"8","author":"TO Cole","year":"2020","unstructured":"Cole TO, Robinson D, Kelley-Freeman A, Gandhi D, Greenblatt AD, Weintraub E, et al. Patient satisfaction with medications for opioid use disorder treatment via telemedicine: brief literature review and development of a new assessment. Front Public Health. 2020;8:557275. https:\/\/doi.org\/10.3389\/fpubh.2020.557275","journal-title":"Front Public Health"},{"issue":"2","key":"1474_CR12","first-page":"5","volume":"23","author":"E Weintraub","year":"2021","unstructured":"Weintraub E, Greenblatt AD, Chang J, Welsh CJ, Berthiaume AP, Goodwin SR, et al. Outcomes for patients receiving telemedicine-delivered medication-based treatment for Opioid use disorder: a retrospective chart review. Heroin Addict Relat Clin Probl. 2021;23(2):5\u201312.","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"1474_CR13","doi-asserted-by":"crossref","unstructured":"Zheng W, Nickasch M, Lander L, Wen S, Xiao M, Marshalek P, et al. Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective Data Analysis. J Addict Med. 2017;11(2):138\u201344.","DOI":"10.1097\/ADM.0000000000000287"},{"issue":"9","key":"1474_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11920-022-01346-z","volume":"24","author":"H Mahmoud","year":"2022","unstructured":"Mahmoud H, Naal H, Whaibeh E, Smith A. Telehealth-based delivery of medication-assisted treatment for opioid use disorder: a critical review of recent developments. Curr Psychiatry Rep. 2022;24(9):375\u201386. https:\/\/doi.org\/10.1007\/s11920-022-01346-z","journal-title":"Curr Psychiatry Rep"},{"key":"1474_CR15","doi-asserted-by":"publisher","first-page":"231190945","DOI":"10.1177\/1357633X231190945","volume":"1357633X","author":"H Pham","year":"2023","unstructured":"Pham H, Lin C, Zhu Y, Clingan SE, Lin LA, Mooney LJ, et al. Telemedicine-delivered treatment for substance use disorder: a scoping review. J Telemed Telecare. 2023;1357633X:231190945. https:\/\/doi.org\/10.1177\/1357633X231190945","journal-title":"J Telemed Telecare"},{"key":"1474_CR16","doi-asserted-by":"publisher","first-page":"231195607","DOI":"10.1177\/1357633X231195607","volume":"1357633X","author":"J Tay Wee Teck","year":"2023","unstructured":"Tay Wee Teck J, Butner JL, Baldacchino A. Understanding the use of telemedicine across different opioid use disorder treatment models: a scoping review. J Telemed Telecare. 2023;1357633X:231195607. https:\/\/doi.org\/10.1177\/1357633X231195607","journal-title":"J Telemed Telecare"},{"key":"1474_CR17","doi-asserted-by":"publisher","unstructured":"Williams AR, Aronowitz,Shoshana V, Rowe, Christopher, Gallagher, Ryan, Behar, Emily, and, Bisaga A. Telehealth for opioid use disorder: retention as a function of demographics and rurality. Am J Drug Alcohol Abuse. 2023;49(2):260\u20135. https:\/\/doi.org\/10.1080\/00952990.2023.2180382","DOI":"10.1080\/00952990.2023.2180382"},{"issue":"10","key":"1474_CR18","doi-asserted-by":"publisher","first-page":"e2336914","DOI":"10.1001\/jamanetworkopen.2023.36914","volume":"6","author":"LR Hammerslag","year":"2023","unstructured":"Hammerslag LR, Mack A, Chandler RK, Fanucchi LC, Feaster DJ, LaRochelle MR, et al. Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for medicaid enrollees. JAMA Netw Open. 2023;6(10):e2336914. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36914.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1474_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12954-021-00572-7","volume":"18","author":"SV Aronowitz","year":"2021","unstructured":"Aronowitz SV, Engel-Rebitzer E, Dolan A, Oyekanmi K, Mandell D, Meisel Z, et al. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. Harm Reduct J. 2021;18(1):119. https:\/\/doi.org\/10.1186\/s12954-021-00572-7","journal-title":"Harm Reduct J"},{"key":"1474_CR20","doi-asserted-by":"publisher","first-page":"112522","DOI":"10.1016\/j.drugalcdep.2024.112522","volume":"266","author":"SV Aronowitz","year":"2025","unstructured":"Aronowitz SV, Zucker N, Thompson M, James R, Clapp J, Mandell D. Patient and provider experiences with opioid use disorder care delivered via telehealth: a systematic mixed-studies review. Drug Alcohol Depend. 2025;266:112522. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112522.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1474_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/ajad.12805","volume":"27","author":"E Weintraub","year":"2018","unstructured":"Weintraub E, Greenblatt AD, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27(8):612\u20137. https:\/\/doi.org\/10.1111\/ajad.12805","journal-title":"Am J Addict"},{"key":"1474_CR22","doi-asserted-by":"publisher","first-page":"103804","DOI":"10.1016\/j.drugpo.2022.103804","volume":"108","author":"SV Aronowitz","year":"2022","unstructured":"Aronowitz SV, Hudgins A. Problematizing patient stability in opioid use disorder care: flexible definitions, (in)flexible treatment. Int J Drug Policy. 2022;108:103804. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103804","journal-title":"Int J Drug Policy"},{"issue":"11","key":"1474_CR23","doi-asserted-by":"publisher","first-page":"e20839","DOI":"10.2196\/20839","volume":"22","author":"MA Hyder","year":"2020","unstructured":"Hyder MA, Razzak J. Telemedicine in the United States: an introduction for students and residents. J Med Internet Res. 2020;22(11):e20839.","journal-title":"J Med Internet Res"},{"issue":"1","key":"1474_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41746-024-01152-2","volume":"7","author":"E Hatef","year":"2024","unstructured":"Hatef E, Wilson RF, Zhang A, Hannum SM, Kharrazi H, Davis SA, et al. Effectiveness of telehealth versus in-person care during the COVID-19 pandemic: a systematic review. npj Digit Med. 2024;7(1):157. https:\/\/doi.org\/10.1038\/s41746-024-01152-2.","journal-title":"npj Digit Med"},{"key":"1474_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jpsychires.2021.11.003","volume":"145","author":"NZ Bulkes","year":"2022","unstructured":"Bulkes NZ, Davis K, Kay B, Riemann BC. Comparing efficacy of telehealth to in-person mental health care in intensive-treatment-seeking adults. J Psychiatr Res. 2022;145:347\u201352. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.11.003.","journal-title":"J Psychiatr Res"},{"issue":"8","key":"1474_CR26","doi-asserted-by":"publisher","first-page":"e37100","DOI":"10.2196\/37100","volume":"24","author":"AA Lewinski","year":"2022","unstructured":"Lewinski AA, Walsh C, Rushton S, Soliman D, Carlson SM, Luedke MW, et al. Telehealth for the longitudinal management of chronic conditions: systematic review. J Med Internet Res. 2022;24(8):e37100. https:\/\/doi.org\/10.2196\/37100.","journal-title":"J Med Internet Res"},{"issue":"4","key":"1474_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.pop","volume":"49","author":"J Shaver","year":"2022","unstructured":"Shaver J. The state of telehealth before and after the COVID-19 pandemic. Prim Care. 2022;49(4):517\u201330. https:\/\/doi.org\/10.1016\/j.pop","journal-title":"Prim Care"},{"issue":"5","key":"1474_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1176\/appi.ps.202100088","volume":"73","author":"TL Mark","year":"2022","unstructured":"Mark TL, Treiman K, Padwa H, Henretty K, Tzeng J, Gilbert M. Addiction treatment and telehealth: review of efficacy and provider insights during the COVID-19 pandemic. PS. 2022;73(5):484\u201391. https:\/\/doi.org\/10.1176\/appi.ps.202100088.","journal-title":"PS"},{"issue":"7","key":"1474_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1177\/02692163231172243","volume":"37","author":"W English","year":"2023","unstructured":"English W, Robinson J, Gott M. Health professionals\u2019 experiences of rapport during telehealth encounters in community palliative care: an interpretive description study. Palliat Med. 2023;37(7):975\u201383. https:\/\/doi.org\/10.1177\/02692163231172243.","journal-title":"Palliat Med"},{"issue":"9","key":"1474_CR30","doi-asserted-by":"publisher","first-page":"e39920","DOI":"10.2196\/39920","volume":"24","author":"PD Koppel","year":"2022","unstructured":"Koppel PD, Gagne JCD, Docherty S, Smith S, Prose NS, Jabaley T. Exploring nurse and patient experiences of developing rapport during oncology ambulatory care videoconferencing visits: qualitative descriptive study. J Med Internet Res. 2022;24(9):e39920. https:\/\/doi.org\/10.2196\/39920.","journal-title":"J Med Internet Res"},{"issue":"2","key":"1474_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jpm11020137","volume":"11","author":"JD Record","year":"2021","unstructured":"Record JD, Ziegelstein RC, Christmas C, Rand CS, Hanyok LA. Delivering personalized care at a distance: how telemedicine can foster getting to know the patient as a person. J Personal Med. 2021;11(2):2. https:\/\/doi.org\/10.3390\/jpm11020137.","journal-title":"J Personalized Med"},{"key":"1474_CR32","doi-asserted-by":"crossref","unstructured":"Zeavin H. The distance cure: a history of teletherapy. MIT Press. 2021:323.","DOI":"10.7551\/mitpress\/12823.001.0001"},{"key":"1474_CR33","doi-asserted-by":"crossref","unstructured":"Zeavin H. Mother media: hot and cool parenting in the Twentieth century. MIT Press. 2025;322.","DOI":"10.7551\/mitpress\/14223.001.0001"},{"key":"1474_CR34","doi-asserted-by":"crossref","unstructured":"Sterne J. The audible past: cultural origins of sound reproduction. Duke University Press. 2003;476.","DOI":"10.1215\/9780822384250"},{"key":"1474_CR35","unstructured":"Aronowitz S, Behrends CN, Lowenstein M, Shackman B, Weiner J. Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach [Internet]. Philadlephia, PA: Leonard Davis Institute of Health Economics; 2022 Jan [cited 2025 May 13]. Available from: https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-9918335064006676-pdf"},{"issue":"1","key":"1474_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13722-022-00342-1","volume":"17","author":"J Carter","year":"2022","unstructured":"Carter J, Li Z, Chen H, Greiner M, Bush C, Bhattacharya D, et al. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study. Addict Sci Clin Pract. 2022;17(1):60. https:\/\/doi.org\/10.1186\/s13722-022-00342-1.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"1474_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000520185","volume":"28","author":"F Chalabianloo","year":"2021","unstructured":"Chalabianloo F, Ohldieck C, Haaland \u00d8A, Fadnes LT, Johansson KA. Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence. Eur Addict Res. 2021;28(3):199\u2013209. https:\/\/doi.org\/10.1159\/000520185.","journal-title":"Eur Addict Res"},{"issue":"2","key":"1474_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95\u201398","journal-title":"J Addict Med"},{"key":"1474_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.socscimed.2019.05.027","volume":"232","author":"EF Madden","year":"2019","unstructured":"Madden EF. Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324\u201331. https:\/\/doi.org\/10.1016\/j.socscimed.2019.05.027.","journal-title":"Soc Sci Med"},{"issue":"14","key":"1474_CR40","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181\u2013201. https:\/\/doi.org\/10.1080\/10826084.2021.1975749.","journal-title":"Subst Use Misuse"},{"key":"1474_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/SAR.S304566","volume":"13","author":"A Cheetham","year":"2022","unstructured":"Cheetham A, Picco L, Barnett A, Lubman DI, Nielsen S. The impact of stigma on people with opioid use disorder, opioid treatment, and policy. Subst Abuse Rehabilitat. 2022;13:1\u201312. 10.2147","journal-title":"Subst Abuse Rehabilitation"},{"key":"1474_CR42","doi-asserted-by":"publisher","first-page":"108627","DOI":"10.1016\/j.drugalcdep.2021.108627","volume":"221","author":"EM Stone","year":"2021","unstructured":"Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians\u2019 treatment of opioid use disorder. Drug Alcohol Depend. 2021;221:108627. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108627.","journal-title":"Drug Alcohol Depend"},{"key":"1474_CR43","doi-asserted-by":"publisher","first-page":"100138","DOI":"10.1016\/j.dadr.2023.100138","volume":"6","author":"A Carl","year":"2023","unstructured":"Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Depend Rep. 2023;6:100138. https:\/\/doi.org\/10.1016\/j.dadr.2023.100138.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"6","key":"1474_CR44","doi-asserted-by":"publisher","first-page":"e2518500","DOI":"10.1001\/jamanetworkopen.2025.18500","volume":"8","author":"SE Wakeman","year":"2025","unstructured":"Wakeman SE. Ongoing gaps in buprenorphine treatment: urgency and opportunity. JAMA Netw Open. 2025;8(6):e2518500. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.18500.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1474_CR45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","volume":"53","author":"SE Wakeman","year":"2018","unstructured":"WakemanSE, Rich JD. Barriers to medications for addiction treatment: How stigma kills. Subst Use Misuse. 2018;53(2):330\u20133. https:\/\/doi.org\/10.1080\/10826084.2017.1363238","journal-title":"Subst Use Misuse"},{"key":"1474_CR46","doi-asserted-by":"publisher","DOI":"10.31478\/202004b","author":"BK Madras","year":"2020","unstructured":"Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020. https:\/\/doi.org\/10.31478\/202004b","journal-title":"NAM Perspect"},{"key":"1474_CR47","doi-asserted-by":"publisher","first-page":"209270","DOI":"10.1016\/j.josat.2023.209270","volume":"159","author":"K McLean","year":"2024","unstructured":"McLean K, Murphy J, Kruis N. I think we\u2019re getting better but we\u2019re still not there: provider-based stigma and perceived barriers to care for people who use opioids (PWUO). J Subst Use Addict Treat. 2024;159:209270. https:\/\/doi.org\/10.1016\/j.josat.2023.209270.","journal-title":"J Subst Use Addict Treat"},{"key":"1474_CR48","doi-asserted-by":"publisher","first-page":"112586","DOI":"10.1016\/j.drugalcdep.2025.112586","volume":"268","author":"M Lowenstein","year":"2025","unstructured":"Lowenstein M, Davis MH, Aronowitz SV, Seeburger E, Grande D. Real-world access to buprenorphine treatment in Philadelphia: a secret shopper study. Drug Alcohol Depend. 2025;268:112586. https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112586.","journal-title":"Drug Alcohol Depend"},{"key":"1474_CR49","unstructured":"Withrow T. Harm reduction under attack in West Virginia West Virginia Watch. West Virginia Watch [Internet]. 2024 Feb 29 [cited 2025 Jul 11]. Available from: https:\/\/westvirginiawatch.com\/2024\/02\/29\/harm-reduction-under-attack-in-west-virginia\/"},{"key":"1474_CR50","doi-asserted-by":"publisher","unstructured":"Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racithnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40(3):367\u201377. https:\/\/doi.org\/10.1007\/s11414-013-9341-3","DOI":"10.1007\/s11414-013-9341-3"},{"issue":"13","key":"1474_CR51","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360. https:\/\/doi.org\/10.1177\/1049732315617444.","journal-title":"Qual Health Res"},{"issue":"4","key":"1474_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun V. Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health. 2019;11(4):589\u201397. https:\/\/doi.org\/10.1080\/2159676X.2019.1628806.","journal-title":"Qualitative Res Sport Exerc Health"},{"key":"1474_CR53","doi-asserted-by":"publisher","unstructured":"Braun V, Clarke V. Thematic analysis. APA handbook of research methods in psychology: research designs: quantitative, qualitative, neuropsychological, and biological. Volume 2, 2nd ed. Washington, DC, US: American psychological association; 2023. 65\u201381. (APA Handbooks in Psychology\u00ae). https:\/\/doi.org\/10.1037\/0000319-004.","DOI":"10.1037\/0000319-004"},{"issue":"5","key":"1474_CR54","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3109\/00952990.2015.1059842","volume":"41","author":"MB Edmond","year":"2015","unstructured":"Edmond MB, Aletraris L, Roman PM. Rural substance use treatment centers in the United States: an assessment of treatment quality by location. Am J Drug Alcohol Abuse. 2015;41(5):449\u201357. https:\/\/doi.org\/10.3109\/00952990.2015.1059842","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1474_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/SAR.S183252","volume":"10","author":"KA Crapanzano","year":"2019","unstructured":"Crapanzano KA, Hammarlund R, Ahmad B, Hunsinger N, Kullar R. The association between perceived stigma and substance use disorder treatment outcomes: a review. Subst Abuse Rehabil. 2019;10:1\u201312","journal-title":"Subst Abuse Rehabil"},{"issue":"1","key":"1474_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12954-024-01043-5","volume":"21","author":"JV Couch","year":"2024","unstructured":"Couch JV, Whitcomb M, Buchheit BM, Dorr DA, Malinoski DJ, Korthuis PT, et al. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis. Harm Reduct J. 2024;21(1):125. https:\/\/doi.org\/10.1186\/s12954-024-01043-5.","journal-title":"Harm Reduct J"},{"key":"1474_CR57","doi-asserted-by":"publisher","unstructured":"Becker A, Doria C, Koenig LR, Ko J, Upadhyay U. It was so easy in a situation that\u2019s so hard: structural stigma and telehealth abortion. J Health Soc Behav. 2025;00221465241303873. https:\/\/doi.org\/10.1177\/00221465241303873.","DOI":"10.1177\/00221465241303873"},{"key":"1474_CR58","doi-asserted-by":"publisher","first-page":"110621","DOI":"10.1016\/j.contraception.2024.110621","volume":"139","author":"M Barnes","year":"2024","unstructured":"Barnes M, Piqueiras E, Gutierrez-Palominos L, Patil R, P042 - A qualitative study exploring patient experiences with telehealth and in-clinic medication abortion. stigma, privacy, and support. Contraception. 2024;139:110621. https:\/\/doi.org\/10.1016\/j.contraception.2024.110621.","journal-title":"Contraception"},{"key":"1474_CR59","doi-asserted-by":"publisher","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","volume":"110","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103786","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1474_CR60","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2105\/AJPH.2021.306577","volume":"112","author":"J Saini","year":"2022","unstructured":"Saini J, Johnson B, Qato DM. Self-reported treatment need and barriers to care for adults with opioid use disorder: The US national survey on drug use and health, 2015 to 2019. Am J Public Health. 2022;112(2):284\u201395. https:\/\/doi.org\/10.2105\/AJPH.2021.306577.","journal-title":"Am J Public Health"},{"issue":"1","key":"1474_CR61","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1186\/s12913-023-10217-z","volume":"23","author":"SE Clingan","year":"2023","unstructured":"Clingan SE, D\u2019Ambrosio BM, Davidson PJ. Patient brokering in for-profit substance use disorder treatment: a qualitative study with people with opioid use disorder and professionals in the field. BMC Health Serv Res. 2023;23(1):1214. https:\/\/doi.org\/10.1186\/s12913-023-10217-z","journal-title":"BMC Health Serv Res"},{"key":"1474_CR62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","volume":"71","author":"K McLean","year":"2019","unstructured":"McLean K, Kavanaugh PR. They\u2019re making it so hard for people to get help: Motivations for non-prescribed buprenorphine use in a time of treatment expansion. Int J Drug Policy. 2019;71:118\u201324. https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.019 . PubMed PMID: 31330267.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1474_CR63","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/jnu.12837","volume":"55","author":"MK McCurry","year":"2023","unstructured":"McCurry MK, Avery-Desmarais S, Schuler M, Tyo M, Viveiros J, Kauranen B. Perceived stigma, barriers, and facilitators experienced by members of the opioid use disorder community when seeking healthcare. J Nurs Scholarsh. 2023;55(3):701\u201310. https:\/\/doi.org\/10.1111\/jnu.12837.","journal-title":"J Nurs Scholarsh"},{"issue":"1","key":"1474_CR64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11469-012-9402-5","volume":"11","author":"V Earnshaw","year":"2013","unstructured":"Earnshaw V, Smith L, Copenhaver M. Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Health Addict. 2013;11(1):110\u201322. https:\/\/doi.org\/10.1007\/s11469-012-9402-5.","journal-title":"Int J Ment Health Addict"},{"key":"1474_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/14659891.2023.2166609","author":"B Tofighi","year":"2023","unstructured":"Tofighi B, Lopez R, Araujo G, Lee JD, Samuels EA, Wightman RS, et al. Provider and administrator attitudes and experiences with implementing telebuprenorphine during the COVID-19 pandemic: a mixed-methods survey. J Subst Use. 2023. https:\/\/doi.org\/10.1080\/14659891.2023.2166609.","journal-title":"J Subst Use"},{"key":"1474_CR66","doi-asserted-by":"publisher","first-page":"102701","DOI":"10.1016\/j.drugpo.2020.102701","volume":"85","author":"HL Cooper","year":"2020","unstructured":"Cooper HL, Cloud DH, Freeman PR, Fadanelli M, Green T, Van Meter C, et al. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020;85:102701. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102701","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1474_CR67","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1363461516660884","volume":"53","author":"S Mendoza","year":"2016","unstructured":"Mendoza S, Rivera-Cabrero AS, Hansen H. Shifting blame: buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. Transcult Psychiatry. 2016;53(4):465\u201387.","journal-title":"Transcult Psychiatry"},{"issue":"2","key":"1474_CR68","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"10118","key":"1474_CR69","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0140-6736","volume":"391","author":"ND Volkow","year":"2018","unstructured":"Volkow ND. Medications for opioid use disorder: bridging the gap in care. Lancet. 2018;391(10118):285\u20137. https:\/\/doi.org\/10.1016\/S0140-6736","journal-title":"Lancet"},{"issue":"7","key":"1474_CR70","doi-asserted-by":"publisher","first-page":"e232247","DOI":"10.1001\/jamahealthforum.2023.2247","volume":"4","author":"AR Williams","year":"2023","unstructured":"Williams AR, Rowe C, Gallagher R, Aronowitz SV, Diamond-Reivich Jon, Bisaga A. Urine drug screening in a telehealth setting for the treatment of opioid use disorder. JAMA Health Forum. 2023;4(7):e232247. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.2247.","journal-title":"JAMA Health Forum"},{"key":"1474_CR71","doi-asserted-by":"publisher","first-page":"209151","DOI":"10.1016\/j.josat.2023.209151","volume":"154","author":"R Rollston","year":"2023","unstructured":"Rollston R, Burke B, Weiner SG, Gallogly W, Brandon AD, Carter R, et al. Evaluation of urine drug screen falsification of results among patients with opioid use disorder receiving treatment in a telehealth model of care. J Subst Use Addict Treat. 2023;154:209151. https:\/\/doi.org\/10.1016\/j.josat.2023.209151","journal-title":"J Subst Use Addict Treat"},{"key":"1474_CR72","doi-asserted-by":"publisher","first-page":"104565","DOI":"10.1016\/j.drugpo.2024.104565","volume":"133","author":"SV Aronowitz","year":"2024","unstructured":"Aronowitz SV, Reed MK. Regressive policing, a return to the war on drugs, and the need for qualitative and ethnographic policy evaluations. Int J Drug Policy. 2024;133:104565. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104565.","journal-title":"Int J Drug Policy"},{"key":"1474_CR73","doi-asserted-by":"publisher","unstructured":"Wakeman SE, McGovern S, Kehoe L, Kane MT, Powell EA, Casey SK, et al. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic. J Subst Abuse Treat. 2022;141. https:\/\/doi.org\/10.1016\/j.jsat.2022.108848 . PubMed PMID: 35926256.","DOI":"10.1016\/j.jsat.2022.108848"},{"key":"1474_CR74","unstructured":"SAMHSA, Advisory. Low barrier models of care for substance use disorders [Internet]. 2023 Dec. Available from: https:\/\/library.samhsa.gov\/sites\/default\/files\/advisory-low-barrier-models-of-care-pep23-02-00-005.pdf"},{"key":"1474_CR75","unstructured":"Orso A, Whelan A, Parker. No city funds for syringe exchanges. Philadelphia Inquirer, The (PA) [Internet]. 2024 Mar 16 [cited 2025 May 12]:1. Located at: Access World News \u2013 Historical and Current. Available from: https:\/\/infoweb.newsbank.com\/apps\/news\/document-view?p=WORLDNEWS&docref=image\/v2%3A1691563DEA998098%40AWNB-197D50F3874364E1%402460386-197D50F41D5805A1%400"},{"key":"1474_CR76","unstructured":"Bauer-Reese J, Kensington Voice, [Internet]. 2024 [cited 2025 May 13]. Kensington Avenue Sunshine House to open despite threats of harm reduction crackdown. Available from: https:\/\/www.kensingtonvoice.com\/en\/kensington-avenue-sunshine-house-to-open-despite-threats-of-harm-reduction-crackdown\/"},{"key":"1474_CR77","unstructured":"Leonard N. Philly City Council gives final OK for mobile van restrictions in Kensington. WHYY [Internet]. 2025 May 8 [cited 2025 May 12]. Available from: https:\/\/whyy.org\/articles\/philadelphia-city-council-kensington-mobile-van-services\/"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01474-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:03:49Z","timestamp":1789124629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01474-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study protocols were reviewed and approved by the University of Pennsylvania Institutional Review Board (IRB), Reference Number 851652.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}